These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12417561)

  • 1. Modeling the benefits of pamidronate in children with osteogenesis imperfecta.
    Lindsay R
    J Clin Invest; 2002 Nov; 110(9):1239-41. PubMed ID: 12417561
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
    Rauch F; Travers R; Plotkin H; Glorieux FH
    J Clin Invest; 2002 Nov; 110(9):1293-9. PubMed ID: 12417568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome: a novel molecular mechanism.
    Namazi H
    J Pediatr Orthop; 2009 Sep; 29(6):650-1. PubMed ID: 19700999
    [No Abstract]   [Full Text] [Related]  

  • 4. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients.
    Roldán EJ; Pasqualini T; Plantalech L
    J Pediatr Endocrinol Metab; 1999; 12(4):555-9. PubMed ID: 10417973
    [No Abstract]   [Full Text] [Related]  

  • 5. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in children with bone diseases.
    Plotkin H
    N Engl J Med; 2003 Nov; 349(21):2068-71; author reply 2068-71. PubMed ID: 14627793
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
    Land C; Rauch F; Glorieux FH
    J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
    Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 11. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
    Aström E; Jorulf H; Söderhäll S
    Arch Dis Child; 2007 Apr; 92(4):332-8. PubMed ID: 17114205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
    N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report.
    Olson JA
    J Pediatr Rehabil Med; 2014; 7(2):155-8. PubMed ID: 25096867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pamidronate treatment for osteogenesis imperfecta in black South Africans.
    Henderson BD; Isaac N; Mabele O; Khiba S; Nkayi A; Mokoena T
    S Afr Med J; 2016 May; 106(6 Suppl 1):S47-9. PubMed ID: 27245525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate administration may result in anaemia in children with osteogenesis imperfecta.
    Michałus I; Nowicka Z; Pietras WA; Nowicka M; Jakubowska-Pietkiewicz E
    Arch Dis Child; 2019 Sep; 104(9):906-907. PubMed ID: 31243011
    [No Abstract]   [Full Text] [Related]  

  • 18. Is APD a promising drug in the treatment of severe osteogenesis imperfecta?
    Huaux JP; Lokietek W
    J Pediatr Orthop; 1988; 8(1):71-2. PubMed ID: 3335625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome.
    Di Iorgi N; Maghnie M
    J Pediatr; 2006 Nov; 149(5):734. PubMed ID: 17095368
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of denosumab on the growing skeleton in osteogenesis imperfecta.
    Hoyer-Kuhn H; Semler O; Schoenau E
    J Clin Endocrinol Metab; 2014 Nov; 99(11):3954-5. PubMed ID: 25148238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.